Email this article 
Cost‑ Effectiveness of Breast Cancer Screening in Shiraz, Iran
Abstract
Background: Breast cancer is the most common cancer in the world, which accounts for 21.4% of all kinds of cancers for women in Iran. However, the treatment of breast cancer is costly and given that the budget devoted to the healthcare sector is limited, the present study aimed to investigate the cost‑effectiveness of breast cancer screening for women, who referred to breast clinic located in Shahid Motahari clinic affiliated to Shiraz University of Medical Sciences, Shiraz city, Iran in 2017‑2018.
Methods: This study is a cross‑sectional study analyzing the cost‑effectiveness of breast cancer screening versus no screening. The study was conducted on 3500 women, who referred to the breast clinic in Motahari clinic, at 2017–2018 in Shiraz, Iran. The patients were identified and direct costs, which were correlated to cancer breast screening, were calculated based on the patients’ records with public tariff per person. Tree age pro 2011 used to analyze cost effectiveness.
Results: Based on the results obtained, the expected cost of screening and no screening were 7556 $ppp and 7840 $ppp, respectively. Given their difference in effectiveness (16%), screening was dominant (less costly and more effective) compared to no screening. Tornado diagram showed that the results had the maximum sensitivity to the increase in screening cost.
Conclusions: In general, according to the results obtained from the current study, the screening was more cost effective compared with no screening.
Keywords
Full Text:
PDFReferences
World Cancer Research Fund International, Available from:
[Internet].https://www.wcrf.org/dietandcancer/breast-cancersurvivors . [Last accessed on 2015 Jul].
Ghaderi I, Kaviani A, Fakhrejahani E, Mehrdad N, Hazar N,
Karbakhsh M. Religious, cultural, and social beliefs of Iranian
rural women about breast cancer: A qualitative study. Archives
of Breast Cancer (ABC) 2014;1:25‑31.
Hatam N, Ahmadloo N, Vazirzadeh M, Jafari A, Askarian M.
Cost‑effectiveness of intensive vs. standard follow‑up models for
patients with breast cancer in Shiraz, Iran. Asian Pac J Cancer
Prev 2016;17:5309.
Montazeri A, Vahdaninia M, Harirchi I, Harirchi AM, Sajadian A,
Khaleghi F, et al. Breast cancer in Iran: Need for greater women
awareness of warning signs and effective screening methods.
Asia Pac Fam Med 2008;7:6.
Derakhshanfar A, Niayesh A, Abbasi M, Ghalaeeha A,
SHojaee M. Frequency of depression in breast cancer
patients: A study in farshchian and besat hospitals of hamedan
during 2007‑8. International Journal of Surgery (IJS)
;21:68‑74. [Persian].
Hatam N, Askarian M, Javan‑Noghabi J, Ahmadloo N,
Mohammadianpanah M. Cost‑utility of “Doxorubicin and
Cyclophosphamide” versus “Gemcitabine and Paclitaxel” for
treatment of patients with breast cancer in Iran. Asian Pac J
Cancer Prev 2015;16:8265‑70.
Nafissi N, Khayamzadeh M, Zeinali Z, Pazooki D, Hosseini M,
Esmaeil Akbari M. Epidemiology and histopathology of breast
cancer in Iran versus other middle Eastern countries. Middle
East J Cancer 2018;9:243‑51.
Raesizadeh M, Seghatoleslami M, Hoseinzade M, Saki
Malehi A. Survival Analysis of Breast Cancer Patients According
to Intermediate and Endpoint Events: Applying IllnessDeath
Model. Iranian Journal of Epidemiology Winter 2018;13:291-8.
Rejali M, Yadegarfar G, Mostajeran M, Aghdak P, Fadaei R,
Ansari R. Evaluation of the status of breast cancer screening
in women in Isfahan province, Iran. Journal of Health System
Research 2016;13:415‑21. [Persian].
Bouya S, Balouchi A, Sudabeh Ahmadidarehsima S,
Badakhsh M. Knowledge and source of information about early
detection techniques of breast cancer among women in Iran:
A systematic review. J Cancer Prev 2018;23:51‑60.
Hatam N, Keshtkar V, Salehi A, Rafei H. The financial cost of
preventive and curative programs for breast cancer: A case study of
women in Shiraz‑Iran. Int J Health Policy Manag 2014;2:187‑91.
Hatam N, Ahmadloo N, Vazirzadeh M, Jafari A, Askarian M.
Cost‑effectiveness of intensive vs. standard follow‑up models for
patients with breast cancer in Shiraz, Iran. Asian Pac J Cancer
Prev 2016;17:5309‑14.
Rim SH, Allaire BT, Ekwueme DU, Miller JW, Subramanian S,
Hall IJ, et al. Cost‑effectiveness of breast cancer screening in
the National breast and cervical cancer early detection program.
Cancer Causes Control 2019;30:819‑26.
Haghighat S, Akbari ME, Yavari P, Javanbakht M, Ghaffari S.
Cost‑effectiveness of three rounds of mammography breast
cancer screening in Iranian women. Iran J Cancer Prev
;9:e5443.
National Center for Chronic Disease Prevention and Health
Promotion (NCCDPHP). [Internet] .https://www.cdc.gov/
chronicdisease/index.htm.[Last accessed on 2018 Feb].
Sun L, Legood R, Sadique Z, dos‑Santos‑Silva I, Yang L.
Cost–effectiveness of risk‑based breast cancer screening
programme, China. Bull World Health Organ 2018;96:568‑77.
[Internet]. https://data.worldbank.org/indicator/PA.NUS.
PPP?locations=IR. [Last access on 2018 Feb].
Davari M, Yazdanpanah F, Aslani A, Hosseini M, Nazari A,
Mokarian F. The Direct Medical Costs of Breast Cancer in
Iran: Analyzing the Patient's Level Data from a Cancer Specific
Hospital in Isfahan. Int J Prev Med. 2013;4:748-54.
Pataky R, Phillips N, Peacock S, Coldman AJ. Cost‑effectiveness
of population‑based mammography screening strategies by age
range and frequency. J Cancer Policy 2014;2:97‑102.
Sankatsing VD, Heijnsdijk EA, Van Luijt PA, Van Ravesteyn NT,
Fracheboud J, De Koning HJ. Cost‐effectiveness of digital
mammography screening before the age of 50 in The
Netherlands. Int J Cancer 2015;137:1990‑9.
Lee SY, Jeong SH, Kim YN, Kim J, Kang DR, Kim H‑C,
et al. Cost‐effective mammography screening in Korea: High
incidence of breast cancer in young women. Cancer Sci
;100:1105‑11.
Rezaianzadeh A, Sepandi M, Akrami M, Tabatabaei H, Rajaeefard A, Tahmasebi S, et al. Pathological profile of patients with breast
diseases in Shiraz. Asian Pac J Cancer Prev 2014;15:8191‑5.
Zare N, Kefayat A, Javanmard SH. Evaluation of radiation and
ammonium lactate effects on hyaluronic acid expression as a
pro‑cancerous factor in supernatant and ex osome isolated from
supernatant of primary mouse fibroblast cell culture. Int J Prev
Med 2020;11:125.
Zahedi H, Djalalinia S, Asayesh H, Mansourian M, Abdar ZE,
Gorabi AM, et al. A higher dietary inflammatory index score
is associated with a higher risk of incidence and mortality of
cancer: A comprehensive systematic review and meta‑analysis.
Int J Prev Med 2020;11:15.